Highlights Eli Lilly and Company

Stocks

LLY

US5324571083

Pharmaceuticals

Market Closed - NYSE Other stock markets 06:02:58 16/07/26 am AEST			After hours 10:00:00 am
1,156.63 ^USD	+0.35%		1,191.72	+3.03%

09:03am	Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports	RE
16/07	Novo Nordisk wins EU approval for Wegovy weight-loss pill	RE

Highlights

09/07	Truist Securities Expects Q2 Beat from Eli Lilly; Price Target, Estimates Up	MT
09/07	Eli Lilly Could Deliver 'Beat-and-Raise' Quarter, Truist Says	MT
09/07	Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says	MT
08/07	RBC Lifts Eli Lilly Price Target on Expected 'Strong' Q2 Performance of Obesity Drugs	MT
08/07	Eli Lilly Says Health Canada Approves Mounjaro for Children With Type 2 Diabetes	MT
06/07	Eli Lilly Products to be Sold, Distributed by DKSH in Hong Kong, Macau	MT
30/06	Hybio's generic weight-loss drug set for FDA review	RE
30/06	Eli Lilly, Innovent Biologics Sign China Distribution Agreement for Verzenios	MT
30/06	Lilly, Regeneron selected for US program to review new manufacturing plants faster	RE
30/06	FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports	RE
30/06	Eli Lilly, Abu Dhabi's Health Department Enter MoU to Manage Obesity, Alzheimer's Disease	MT
26/06	Eli Lilly And Company Receives Positive Opinion From CHMP For Jaypirca For Treatment Of Adults With Chronic Lymphocytic Leukemia Across All Lines Of Therapy	CI
26/06	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT
26/06	Eli Lilly's Blood Cancer Therapy Recommended for EU Approval	MT
26/06	Eli Lilly Unit's Once-weekly Insulin Recommended for EU Approval	MT
25/06	Eli Lilly Completes Acquisition of Centessa Pharmaceuticals	MT
24/06	Abbisko Cayman Limited and Eli Lilly and Company Deepen R&D Collaboration	CI
24/06	Eli Lilly Sees Weight-loss Pill Approval in China by 2026-end	MT
24/06	Eli Lilly Signs Strategic Research, License Deal With Abbisko Therapeutics	MT
24/06	Eli Lilly and Company entered into asset sale agreement to acquire Certain Assets from Sangamo Therapeutics, Inc..	CI
23/06	Eli Lilly, Astellas Enter Into Asset Sale Agreements With Sangamo Therapeutics	MT
23/06	UK High Court Approves Lilly's $7.8 Billion Acquisition of Centessa	MT
23/06	Eli Lilly Reports Long-Term Data for Lebrikizumab in Atopic Dermatitis	CI
23/06	Eli Lilly Keeps Quarterly Dividend at $1.73 a Share, Payable Sept. 10 to Holders of Record Aug. 14	MT
23/06	Eli Lilly and Company Declares Dividend for the Third Quarter of 2026, Payable on September 10, 2026	CI